Anti-Influenza Serum and Mucosal Antibody Responses After Administration of Live Attenuated or Inactivated Influenza Vaccines to HIV-Infected Children
- 1 October 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 55 (2), 189-196
- https://doi.org/10.1097/qai.0b013e3181e46308
Abstract
Background: Live-attenuated influenza vaccine (LAIV) prevents more cases of influenza in immune-competent children than the trivalent inactivated vaccine (TIV). We compared the antibody responses to LAIV or TIV in HIV-infected children. Methods: Blood and saliva obtained at enrollment, 4 and 24 weeks postimmunization from 243 HIV-infected children randomly assigned to TIV or LAIV were analyzed. Results: Both vaccines increased the anti-influenza neutralizing antibodies at 4 and 24 weeks postimmunization. At 4 weeks postimmunization, TIV recipients had 2-fold to 3-fold higher neutralizing antibody titers than LAIV recipients, but the proportions of subjects with protective titers (≥1:40) were similar between treatment groups (96%-100% for influenza A and 81%-88% for influenza B). Both vaccines increased salivary homotypic IgG antibodies, but not IgA antibodies. Both vaccines also increased serum heterosubtypic antibodies. Among HIV-specific characteristics, the baseline viral load correlated best with the antibody responses to either vaccine. We used LAIV-virus shedding as a surrogate of influenza infection. Influenza-specific humoral and mucosal antibody levels were significantly higher in nonshedders than in shedders. Conclusions: LAIV and TIV generated homotypic and heterosubtypic humoral and mucosal antibody responses in HIV-infected children. High titers of humoral or mucosal antibodies correlated with protection against viral shedding.This publication has 29 references indexed in Scilit:
- Comparative Efficacy of Inactivated and Live Attenuated Influenza VaccinesThe New England Journal of Medicine, 2009
- Efficacy and Safety of 1 and 2 Doses of Live Attenuated Influenza Vaccine in Vaccine-Naive ChildrenThe Pediatric Infectious Disease Journal, 2009
- Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trialsVaccine, 2009
- Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected childrenVaccine, 2008
- Correlation of Cellular Immune Responses with Protection against Culture-Confirmed Influenza Virus in Young ChildrenClinical and Vaccine Immunology, 2008
- Induction of Heterosubtypic Immunity to Influenza Virus by Intranasal ImmunizationJournal of Virology, 2008
- Efficacy and Safety of a Live Attenuated, Cold-Adapted Influenza Vaccine, Trivalent Against Culture-Confirmed Influenza in Young Children in AsiaThe Pediatric Infectious Disease Journal, 2007
- Prevention of Antigenically Drifted Influenza by Inactivated and Live Attenuated VaccinesThe New England Journal of Medicine, 2006
- Induction of Mucosal Antibodies by Live Attenuated and Inactivated Influenza Virus Vaccines in the Chronically III ElderlyThe Journal of Infectious Diseases, 1996
- A Randomized Controlled Trial of Cold-Adapted and Inactivated Vaccines for the Prevention of Influenza A DiseaseThe Journal of Infectious Diseases, 1994